Table 1.
Normal |
HF |
|||
---|---|---|---|---|
Control | After irbesartan | Control | After irbesartan | |
dBP vs. HR | ||||
Maximum slope | −4.2 ± 0.6 | −5.3 ± 0.8 | −2.78 ± 0.3* | −3.14 ± 0.6 |
Top plateau | 153 ± 13 | 159 ± 7 | 125 ± 9* | 118 ± 10 |
Bottom plateau | 51 ± 3 | 52 ± 3 | 53 ± 4 | 57 ± 4 |
BP50 | 69 ± 3 | 58 ± 2† | 70 ± 4 | 61 ± 2† |
Threshold | 84 ± 3 | 74 ± 3† | 91 ± 4 | 77 ± 4† |
Saturation | 53 ± 5 | 43 ± 2† | 50 ± 6 | 44 ± 2 |
dBP vs. CSNA | ||||
Maximum slope | −9.9 ± 3.2 | −6.0 ± 1.3 | −6.9 ± 1.1 | −4.3 ± 0.6† |
BP50 | 70 ± 2 | 61 ± 2† | 74 ± 4 | 67 ± 4† |
Threshold | 83 ± 4 | 77 ± 3 | 87 ± 4 | 87 ± 7 |
Saturation | 59 ± 4 | 46 ± 3† | 61 ± 5 | 47 ± 5† |
Values are means ± SE (n = 7). HF, heart failure; HR, heart rate; CSNA, cardiac sympathetic nerve activity; dBP, diastolic blood pressure; BP50, pressure at 50% of maximum CSNA.
P < 0.05 vs. normal.
P < 0.05 vs. control.